The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Newly approved drugs for AML in the US
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden, Naval Daver, MD, of MD Anderson Cancer Center, Houston, TX, discusses four new drugs that have recently been approved in the US. These are: midostaurin, a FLT3 inhibitor to be used with induction chemotherapy for FLT3-mutated AML; enasidenib, an IDH2 inhibitor for relapsed IDH2-mutated AML that can be taken orally; gemtuzumab ozogamicin, an antibody-drug conjugate that targets cells expressing CD33; and the combination of cytarabine and daunorubicin, which increases bone marrow penetration and survival compared to the previous standard of care.
